AbCellera Biologics Inc. (ABCL) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody medicines. The company operates a dual strategy: advancing an internal pipeline of drug candidates (including ABCL635 and ABCL575) and partnering with pharmaceutical companies to discover antibodies for their pipelines. As of August 3, 2026, the company had approximately 306.6 million common shares outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) |
|---|---|---|
| Total Revenue | $4.05 million | $12.36 million |
| Net Loss | $(55.43) million | $(98.59) million |
| Loss Per Share (Basic & Diluted) | $(0.18) | $(0.32) |
| Operating Expenses | $66.83 million | $132.66 million |
| Cash, Cash Equivalents & Marketable Securities | $540.10 million (as of June 30, 2026) | |
| Net Cash Used in Operating Activities | $(7.60) million (YTD 2026) |
Note: Revenue consists of Research fees ($3.90M Q2 / $12.02M YTD) and Licensing/royalty revenue ($0.15M Q2 / $0.34M YTD). Operating expenses include R&D ($45.99M Q2 / $92.65M YTD) and SG&A ($13.85M Q2 / $26.19M YTD).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 76% ($13.0 million) in Q2 2026 compared to Q2 2025. This was primarily driven by a 99% drop in licensing and royalty revenue, which was $10.45 million in Q2 2025 versus $0.15 million in Q2 2026. Research fees also declined 41%.
- Increased Net Loss: Net loss widened to $55.4 million in Q2 2026 from $34.7 million in Q2 2025. This increase was driven by higher R&D expenses (up 17%) and a significant reduction in "Interest and other income," which dropped from $9.5 million in Q2 2025 to negligible amounts in Q2 2026 due to foreign exchange fluctuations and lower interest yields.
- SG&A Reduction: Sales, general, and administrative expenses decreased by 37% ($8.1 million) in Q2 2026 compared to the prior year, attributed to headcount optimization and a reduction in legal fees following a settlement in late 2025.
- Liquidity Improvement: Despite operating losses, total cash and marketable securities increased to $540.1 million from $533.8 million at year-end 2025. This was bolstered by the full collection of a $36.0 million litigation settlement and a $56.0 million upfront payment from a new collaboration.
Guidance, Outlook, and Recent Developments
- New Collaborations:
- Jazz Pharmaceuticals (June 2026): Entered a preclinical research collaboration for T-cell engaging multispecific antibodies. AbCellera received a $56.0 million non-refundable upfront payment, with an additional $28.0 million due upon initiating a third program. Potential future milestones total up to $792.0 million per program.
- Vertex Pharmaceuticals (July 2026): Entered a collaboration to develop multispecific T-cell engagers for autoimmune diseases. AbCellera received $28.0 million in upfront payments.
- Clinical Pipeline Updates:
- ABCL635 (Menopause/VMS): Positive interim Phase 1 data announced in May 2026 showing potent target engagement and favorable safety. Phase 2 enrollment is complete, with top-line data expected in August 2026.
- ABCL575 (Immunology): Phase 1 dosing completed; top-line data expected in Q4 2026.
- ABCL688 & ABCL386: Advanced into IND/CTA-enabling studies with anticipated Phase 1/2 initiation in 2027.
- Liquidity Outlook: Management believes current cash, marketable securities, and government contributions are sufficient to fund operations and capital expenditures for at least the next 36 months.
- Risks: Key risks include the uncertainty of clinical trial outcomes (specifically the August 2026 ABCL635 readout), reliance on partners for downstream revenue, and potential volatility in share price due to clinical milestones. The company also faces risks related to global conflicts impacting supply chains and costs.
Investor Verification Checklist
- Verify the timing and results of the ABCL635 Phase 2 top-line data expected in August 2026, as this is a critical near-term catalyst.
- Confirm the recognition timeline for the $56.0 million Jazz Pharmaceuticals and $28.0 million Vertex Pharmaceuticals upfront payments to understand future revenue visibility.
- Monitor the status of the Schrader litigation, noting that while patent infringement allegations were removed, the company is still defending against remaining claims.
- Review the government contribution agreements (Canada and British Columbia) to understand the conditions for repayment and the availability of undrawn funding (~$110 million USD).
- Assess the impact of foreign exchange rates on future earnings, given the company's significant operations in Canada and revenue in USD.